Foundation Resource Management Inc. Has $6.21 Million Stake in AbbVie Inc. (NYSE:ABBV)
Foundation Resource Management Inc. Has $6.21 Million Stake in AbbVie Inc. (NYSE:ABBV)
Foundation Resource Management Inc. lowered its position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 0.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,557 shares of the company's stock after selling 80 shares during the period. Foundation Resource Management Inc.'s holdings in AbbVie were worth $6,212,000 at the end of the most recent reporting period.
基金资源管理公司最近提交给美国证券交易委员会的文件显示，该公司在第二季度将其持有的艾伯维公司股票的仓位下调了0.2%。该基金在此期间出售了80股后，持有该公司40,557股股票。在最近一次报告期结束时，基金会资源管理公司在AbbVie持有的股份价值6,211,000美元。
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Intelligent Financial Strategies bought a new position in AbbVie in the 4th quarter valued at approximately $27,000. Psagot Value Holdings Ltd. Israel raised its holdings in AbbVie by 311.3% in the 4th quarter. Psagot Value Holdings Ltd. Israel now owns 4,360 shares of the company's stock valued at $28,000 after buying an additional 3,300 shares during the last quarter. GoalVest Advisory LLC bought a new position in AbbVie in the 1st quarter valued at approximately $33,000. Joseph P. Lucia & Associates LLC bought a new position in AbbVie in the 1st quarter valued at approximately $34,000. Finally, Landmark Wealth Management LLC bought a new position in AbbVie in the 1st quarter valued at approximately $42,000. Institutional investors and hedge funds own 68.25% of the company's stock.
其他一些机构投资者和对冲基金也买卖了该公司的股票。智能财务策略公司在第四季度购买了AbbVie的一个新头寸，价值约为27,000美元。以色列Psagot Value控股有限公司在第四季度将其在AbbVie的持股增加了311.3%。以色列Psagot Value Holdings Ltd.在上个季度又购买了3,300股Psagot Value Holdings Ltd.股票后，现在持有该公司4,360股股票，价值28,000美元。GoalVest Consulting LLC在第一季度购买了AbbVie的一个新头寸，价值约为3.3万美元。Joseph P.Lucia&Associates LLC在第一季度购买了AbbVie的一个新头寸，价值约3.4万美元。最后，Landmark Wealth Management LLC在第一季度购买了AbbVie的一个新头寸，价值约为42,000美元。机构投资者和对冲基金持有该公司68.25%的股票。
AbbVie Stock Performance
艾伯维股票表现
Shares of ABBV stock opened at $143.06 on Friday. The company has a market cap of $252.94 billion, a price-to-earnings ratio of 20.26, a price-to-earnings-growth ratio of 4.02 and a beta of 0.72. AbbVie Inc. has a 52 week low of $106.44 and a 52 week high of $175.91. The company has a quick ratio of 0.75, a current ratio of 0.84 and a debt-to-equity ratio of 4.15. The firm has a 50 day moving average of $141.77 and a 200-day moving average of $149.53.
上周五，ABBV股票开盘报143.06美元。该公司市值为2,529.4亿美元，市盈率为20.26倍，市盈率为4.02倍，贝塔系数为0.72。AbbVie Inc.的52周低点为106.44美元，52周高点为175.91美元。该公司的速动比率为0.75，流动比率为0.84，债务权益比为4.15。该公司的50日移动均线切入位在141.77美元，200日移动均线切入位在149.53美元。
AbbVie Announces Dividend
AbbVie宣布分红
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 15th. Investors of record on Friday, October 14th will be given a $1.41 dividend. This represents a $5.64 annualized dividend and a yield of 3.94%. The ex-dividend date of this dividend is Thursday, October 13th. AbbVie's payout ratio is currently 79.89%.
该公司最近还宣布了季度股息，将于11月15日(星期二)支付。10月14日(星期五)登记在册的投资者将获得1.41美元的股息。这意味着5.64美元的年化股息和3.94%的收益率。本次股息除息日期为10月13日星期四。AbbVie的派息率目前为79.89%。
Analysts Set New Price Targets
分析师设定新的价格目标
ABBV has been the subject of a number of research reports. UBS Group dropped their price objective on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a report on Monday, August 1st. Atlantic Securities lowered their price target on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a report on Monday, August 1st. Morgan Stanley lowered their price target on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a report on Monday, August 1st. Argus lowered their price target on shares of AbbVie from $165.00 to $155.00 and set a "buy" rating for the company in a report on Wednesday, August 24th. Finally, Barclays lowered their price target on shares of AbbVie to $160.00 in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $159.35.
ABBV已经成为许多研究报告的主题。瑞银集团在8月1日周一的一份报告中将艾伯维股票的目标价从154.00美元下调至146.00美元，并将该公司的评级定为“中性”。大西洋证券在8月1日周一的一份报告中将AbbVie的股票目标价从178.00美元下调至162.00美元，并将该公司的评级定为“中性”。摩根士丹利在8月1日周一的一份报告中将艾伯维股票的目标价从191.00美元下调至188.00美元，并对该公司设定了“增持”评级。Argus在8月24日周三的一份报告中将AbbVie的股票目标价从165.00美元下调至155.00美元，并对该公司设定了“买入”评级。最后，巴克莱在8月9日周二的一份报告中将艾伯维的目标股价下调至160.00美元。一名投资分析师对该股的评级为卖出，六名分析师给予持有评级，九名分析师给予买入评级，一名分析师给予该公司强烈买入评级。根据MarketBeat.com的数据，该股目前的平均评级为“中等买入”，平均目标价为159.35美元。
About AbbVie
关于AbbVie
(Get Rating)
(获取评级)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯维公司在世界各地发现、开发、制造和销售药品。该公司提供HUMIRA，用于注射治疗自身免疫和肠道Behçet‘s疾病；SKYRIZI用于治疗成人中到重度斑块型牛皮癣；RINVOQ，用于治疗成人患者的中到重度活动性类风湿性关节炎；IMBRUVICA，用于治疗成人慢性淋巴细胞白血病和小淋巴细胞淋巴瘤；以及VENCLEXTA，用于治疗成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- 免费获取StockNews.com关于AbbVie的研究报告(ABBV)
- 华尔街对Datadog的热情会带来巨大的收益吗？
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 小盘股的裁员是楼市的晴雨表吗？
- 需要关注的2只半导体类股走势逆转
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AbbVie和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。